Prosecution Insights
Prosecution Insights
59 pending office actions • 27 art units • 49 examiners • 1 of 59 (2%) have an AI response strategy ready • 70 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 58 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 58 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 28 (47%) |
| §102 only | 5 (8%) |
| §112 only | 6 (10%) |
| No statute on record | 20 (34%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEJIAS, SAMANTHA LEE | 2 | 47.4% | +62.5% |
| YOUNG, MICAH PAUL | 2 | 55.1% | +30.1% |
| HUYNH, PHUONG N | 2 | 65.7% | +53.3% |
| HOWARD, ZACHARY C | 2 | 63.9% | +38.2% |
| NATARAJAN, MEERA | 2 | 62.2% | +16.8% |
| KAUFMAN, CLAIRE M | 2 | 62.8% | +51.3% |
| DONOHUE, SEAN R | 2 | 41.5% | +21.7% |
| WANG, CHANG YU | 2 | 33.6% | +53.0% |
| BERHANE, SELAM | 2 | 61.3% | +55.5% |
| DEBERRY, REGINA M | 2 | 49.8% | +30.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17609261 | ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS | BERHANE, SELAM | 127d overdue |
| 17753850 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | MEJIAS, SAMANTHA LEE | 85d overdue |
| 16761513 | METHOD OF TREATING HIDRADENTITIS SUPPURATIVA WITH IL-17 ANTAGONISTS | DEBERRY, REGINA M | 78d overdue |
| 17997299 | METHODS FOR RADIOLABELING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 71d overdue |
| 17997295 | METHODS FOR RADIOLABELLING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 70d overdue |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | WANG, CHANG YU | 60d overdue |
| 18251913 | ANTIBODY Fc VARIANTS | HOWARD, ZACHARY C | 37d overdue |
| 17995820 | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG | WANG, CHANG YU | 35d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 8 |
| 1643 | 6 |
| 1674 | 6 |
| 1675 | 4 |
| 1627 | 3 |
| 1628 | 3 |
| 3683 | 2 |
| 1641 | 2 |
| 1624 | 2 |
| 1691 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19326445 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | SAMALA, JAGADISHWAR RAO | 1618 | Other | Non-Final OA | 1d overdue | Pending | Sep 11, 2025 |
| 19240908 | METHOD OF TREATING PROSTATE CANCER | PERREIRA, MELISSA JEAN | 1618 | §103 | Final Rejection | 32d overdue | Pending | Jun 17, 2025 |
| 19234864 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | 76d | Pending | Jun 11, 2025 |
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | YOUNG, MICAH PAUL | 1618 | §102 | Non-Final OA | 41d | Pending | Apr 11, 2025 |
| 18977210 | Ribociclib Tablet | FUBARA, BLESSING M | 1613 | Other | Non-Final OA | 88d overdue | Pending | Dec 11, 2024 |
| 18667421 | DIGITAL SOLUTIONS FOR DIFFERENTIATING ASTHMA FROM COPD | GILLIGAN, CHRISTOPHER L | 3683 | §103 | Final Rejection | 35d overdue | Pending | May 17, 2024 |
| 18629314 | COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION | HUYNH, PHUONG N | 1641 | §103 | Non-Final OA | 30d overdue | Pending | Apr 08, 2024 |
| 18694271 | A COMPUTER IMPLEMENTED METHOD FOR ASSESSING AND DETERMINING A COMPLEXITY LEVEL OF A CLINICAL TRIAL STUDY | WEBB, JESSICA MARIE | 3683 | §103 | Non-Final OA | 107d overdue | Pending | Mar 21, 2024 |
| 18426461 | Novel Heteroaryl Aminopropanol Derivatives | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | 26d | Pending | Jan 30, 2024 |
| 18561444 | FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE | RAO, SAVITHA M | 1691 | Other | Non-Final OA | 8d overdue | Pending | Nov 16, 2023 |
| 18510836 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | LEWIS, PATRICK T | 1691 | §103 | Non-Final OA | 22d | Pending | Nov 16, 2023 |
| 18558766 | IPTACOPAN FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME | HERNANDEZ, JACKSON J | 1627 | Other | Final Rejection | 17d overdue | Pending | Nov 03, 2023 |
| 18558415 | ALPELISIB FORMULATION | JUSTICE, GINA CHIEUN YU | 1617 | §103 | Non-Final OA | 28d | Pending | Nov 01, 2023 |
| 18557772 | HYPERSIALYLATING CELLS | BERKE-SCHLESSEL, DAVID W | 1651 | §103 | Non-Final OA | 28d | Pending | Oct 27, 2023 |
| 18554778 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | BORALSKY, LUKE ALAN | 1624 | Other | Non-Final OA | 53d overdue | Pending | Oct 10, 2023 |
| 18286030 | OFATUMUMAB FOR TREATING MULTIPLE SCLEROSIS IN ASIAN PATIENTS | CHHAY, BONIRATH | 1645 | Other | Non-Final OA | 34d | Pending | Oct 06, 2023 |
| 18551739 | "Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B" | SHIM, DAVID M. | 1626 | §112 | Non-Final OA | 73d overdue | Pending | Sep 21, 2023 |
| 18551699 | NOVEL CYCLOPENTA[C]PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B | RAO, PADMAJA S | 1627 | §112 | Non-Final OA | 70d overdue | Pending | Sep 21, 2023 |
| 18551033 | NEW PROCESS FOR THE SYNTHESIS OF 5-{5-CHLORO-2-[(3S)-3-[(MORPHOLIN-4-YL)METHYL]-3,4-DIHYDROISOQUINOLINE-2(1H)- CARBONYL]PHENYL}-1,2-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND ITS APPLICATION FOR THE PRODUCTION OF PHARMACEUTICAL COMPOUNDS | SEAMAN, D MARGARET M | 1625 | §102 | Non-Final OA | 34d | Pending | Sep 18, 2023 |
| 17997137 | CCR7 ANTIBODY DRUG CONJUGATES FOR TREATING CANCER | SKOKO III, JOHN JOSEPH | 1643 | Other | Non-Final OA | 14d | Pending | Aug 08, 2023 |
| 18363207 | NLRP3 INFLAMMASOME INHIBITORS | HEES, OLIVER DRAGON | 1628 | §112 | Non-Final OA | 9d | Pending | Aug 01, 2023 |
| 18261523 | PHARMACEUTICAL COMPOSITION | GOTFREDSON, GAREN | 1619 | §102 | Non-Final OA | 27d | Pending | Jul 14, 2023 |
| 18253903 | EXPRESSION TECHNOLOGY FOR ANTIBODY CONSTRUCTS | MONTANARI, DAVID A | 1632 | §103 | Non-Final OA | 55d | Pending | May 22, 2023 |
| 18251913 | ANTIBODY Fc VARIANTS | HOWARD, ZACHARY C | 1674 | Other | Non-Final OA | 37d overdue | Pending | May 05, 2023 |
| 18035472 | ANTI-CD19 AGENT AND B CELL TARGETING AGENT COMBINATION THERAPY FOR TREATING B CELL MALIGNANCIES | NATARAJAN, MEERA | 1643 | Other | Non-Final OA | 2d overdue | Pending | May 04, 2023 |
| 18306958 | MULTISPECIFIC ANTIBODIES TARGETING IL-13 AND IL-18 | O'BRIEN, LEA S | 1646 | Other | Non-Final OA | 36d | Pending | Apr 25, 2023 |
| 18187242 | USE OF CANAKINUMAB | HOWARD, ZACHARY C | 1674 | §102 | Non-Final OA | 34d | Pending | Mar 21, 2023 |
| 18178886 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | HUYNH, PHUONG N | 1641 | Other | Final Rejection | 15d overdue | Pending | Mar 06, 2023 |
| 18019467 | TREATMENT OF CLL | KAUFMAN, CLAIRE M | 1674 | Other | Final Rejection | 6d | Pending | Feb 02, 2023 |
| 18019469 | TREATMENT OF B CELL MALIGNANCIES | KAUFMAN, CLAIRE M | 1674 | Other | Final Rejection | 6d | Pending | Feb 02, 2023 |
| 18006894 | HETEROARYL SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | TOWNSLEY, SARA ELIZABETH | 1629 | §103 | Final Rejection | 56d overdue | Pending | Jan 26, 2023 |
| 18005364 | MAVOGLURANT, A MGLUR5 ANTAGONIST, FOR USE IN THE TREATMENT IN THE REDUCTION OF OPIOID USE | HOWELL, THEODORE R | 1628 | §103 | Final Rejection | 7d | Pending | Jan 13, 2023 |
| 18002572 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | CORNET, JEAN P | 1628 | §103 | Final Rejection | 4d overdue | Pending | Dec 20, 2022 |
| 18061824 | COMBINATION THERAPIES | CANELLA, KAREN A | 1643 | §103 | Non-Final OA | 33d | Pending | Dec 05, 2022 |
| 18061221 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | WU, JULIE ZHEN QIN | 1643 | Other | Non-Final OA | 49d | Pending | Dec 02, 2022 |
| 17998391 | THERAPEUTIC COMBINATIONS COMPRISING A CRAF INHIBITOR | MCKOY, QUINCY ANDRE | 1626 | §103 | Final Rejection | 93d overdue | Pending | Nov 10, 2022 |
| 17997482 | ENGINEERED IMMUNOGLOBULINS | NATARAJAN, MEERA | 1643 | §102 | Non-Final OA | 21d | Pending | Oct 28, 2022 |
| 17997295 | METHODS FOR RADIOLABELLING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | 70d overdue | Pending | Oct 27, 2022 |
| 17997299 | METHODS FOR RADIOLABELING PSMA BINDING LIGANDS AND THEIR KITS | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | 71d overdue | Pending | Oct 27, 2022 |
| 17938846 | METHODS OF TREATING NEW-ONSET PLAQUE TYPE PSORIASIS USING IL-17 ANTAGONISTS | FORD, VANESSA L | 1674 | Other | Non-Final OA | 32d overdue | Pending | Oct 07, 2022 |
| 17995820 | OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG | WANG, CHANG YU | 1675 | Other | Non-Final OA | 35d overdue | Pending | Oct 07, 2022 |
| 17760298 | THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR FOR USE IN TREATING BRAF MUTANT NSCLC | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Final Rejection | 58d overdue | Pending | Aug 05, 2022 |
| 17786347 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | HILL, KEVIN KAI | 1638 | §112 | Non-Final OA | 49d overdue | Pending | Jun 16, 2022 |
| 17771353 | CRIZANLIZUMAB CONTAINING ANTIBODY FORMULATIONS | BERHANE, SELAM | 1675 | Other | Final Rejection | — | Pending | Apr 22, 2022 |
| 17754059 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | 4d overdue | Pending | Mar 22, 2022 |
| 17753850 | METHODS FOR RADIOLABELLING GRPR ANTAGONISTS AND THEIR KITS | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | 85d overdue | Pending | Mar 16, 2022 |
| 17753635 | Management of conditions other than multiple sclerosis in ofatumumab-treated patients | WANG, CHANG YU | 1675 | Other | Non-Final OA | 60d overdue | Pending | Mar 09, 2022 |
| 17640293 | THERAPEUTIC FUSION PROTEINS | DEBERRY, REGINA M | 1647 | Other | Final Rejection | 19d overdue | Pending | Mar 03, 2022 |
| 17639862 | TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS | SAOUD, CHRISTINE J | 1645 | §103 | Final Rejection | 114d overdue | Pending | Mar 02, 2022 |
| 17629286 | REGULATABLE EXPRESSION SYSTEMS | LEVIN, JOEL D | 1633 | §103 | Final Rejection | 15d | Pending | Jan 21, 2022 |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NICKOL, GARY B | 1643 | §112 | Non-Final OA | 15d overdue | Pending | Dec 20, 2021 |
| 17613889 | METHOD FOR NAVIGATING MEDICAL DATA | LAM, ELIZA ANNE | 3681 | §103 | Non-Final OA | 2d overdue | Pending | Nov 23, 2021 |
| 17609261 | ANTI-CD40 ANTIBODIES FOR USE IN TREATMENT OF TIDM AND INSULITIS | BERHANE, SELAM | 1675 | §103 | Final Rejection | 127d overdue | Pending | Nov 05, 2021 |
| 17433812 | MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY | EBBINGHAUS, BRIANA NOEL | 1632 | §103 | Non-Final OA | 30d overdue | Pending | Aug 25, 2021 |
| 17421747 | LTA4H INHIBITORS FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA | CHANNAVAJJALA, LAKSHMI SARADA | 1611 | §103 | Final Rejection | 114d overdue | Pending | Jul 09, 2021 |
| 17309403 | AAV VIRAL VECTORS AND USES THEREOF | RIGA, MICHAEL ANGELO | 1634 | §103 | Non-Final OA | 66d overdue | AI Ready | May 25, 2021 |
| 17292881 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | SCHMIDT, IZABELA MARIA | 1621 | Other | Non-Final OA | 119d overdue | Pending | May 11, 2021 |
| 17161929 | CHO CELL EXPRESSED HET IL-15 | CARTER, SANDRA DILLAHUNT | 1674 | §103 | Non-Final OA | 86d overdue | Pending | Jan 29, 2021 |
| 16761513 | METHOD OF TREATING HIDRADENTITIS SUPPURATIVA WITH IL-17 ANTAGONISTS | DEBERRY, REGINA M | 1647 | §103 | Final Rejection | 78d overdue | Pending | May 05, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial